Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
The recent advances in EGFR M+ NSCLC and the availability of different treatment options, including treatment novelities such as osimertinib and afatinib, are summarized in this review.
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Subjects: | |
| Online Access: | https://onco-hema.healthbooktimes.org/article/24422-critical-review-of-egfr-mutated-nsclc-what-we-do-and-do-not-know |
| Summary: | The recent advances in EGFR M+ NSCLC and the availability of different treatment options, including treatment novelities such as osimertinib and afatinib, are summarized in this review. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |